Anthony J. Krick - 28 Feb 2024 Form 4 Insider Report for OptiNose, Inc. (OPTN)

Reporting relationship: Chief Accounting Officer
Issuer ticker: OPTN
Reported as of: 28 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Feb 2024, 16:07:07 UTC
Prior SEC filing: 10 Mar 2023
Next SEC filing: 19 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Anthony Krick

Key filing fact

Anthony J. Krick filed Form 4 for OptiNose, Inc. (OPTN) on 29 Feb 2024.

Key facts

This page summarizes Anthony J. Krick's Form 4 filing for OptiNose, Inc. (OPTN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Feb 2024, 16:07.

Change

Previous filing in this sequence was filed on 10 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OPTN transaction

Common Stock

Award

Transaction value: $0
Shares: +112,500
Change %: +333%
Price: $0.000000
Shares after: 146,333
Date: 28 Feb 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OPTN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +56,250
Change %
Price: $0.000000
Shares after: 56,250
Date: 28 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 56,250
Exercise price: $1.82
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on February 28, 2025, and the balance vests in equal quarterly installments over the remaining three years of the four year period, subject to continued service with the Issuer provided that, in the event certain minimum performance criteria related to the net revenue and operating profit of OptiNose, Inc. are achieved, then any unvested RSUs shall become fully-vested subject to the Executive's continued service through such date. Each RSU represents the right to receive one share of common stock of OptiNose, Inc.

Footnote F2

The option vests and becomes exercisable over a four-year period commencing on February 28, 2024. Twenty-five percent (25%) of the option vests and becomes exercisable on February 28, 2025, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.